Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients

Survivin is an inhibitor of apoptosis. Aberrant survivin expression occurs in malignant tumors and has often been linked to unfavorable patient outcome. Here we analyzed 12 432 prostate cancers by immunohistochemistry. Survivin immunostaining was regularly expressed at high levels in normal prostate...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Cancer Med
Główni autorzy: Büscheck, Franziska, Sulimankhil, Mariam, Melling, Nathaniel, Höflmayer, Doris, Hube‐Magg, Claudia, Simon, Ronald, Göbel, Cosima, Hinsch, Andrea, Weidemann, Sören, Izbicki, Jacob R., Jacobsen, Frank, Mandelkow, Tim, Blessin, Niclas C., Möller‐Koop, Christina, Lutz, Florian, Viehweger, Florian, Möller, Katharina, Sauter, Guido, Lennartz, Maximillian, Burandt, Eike, Lebok, Patrick, Minner, Sarah, Bonk, Sarah, Huland, Hartwig, Graefen, Markus, Schlomm, Thorsten, Fraune, Christoph
Format: Artigo
Język:Inglês
Wydane: John Wiley and Sons Inc. 2020
Hasła przedmiotowe:
Clinical Cancer Research
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013067/
https://ncbi.nlm.nih.gov/pubmed/31893572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2773
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy